Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 46 to 49 of 49 results for pemetrexed

  1. Nintedanib for untreated malignant pleural mesothelioma [ID1424]

    Discontinued Reference number: GID-TA10359

    Technology appraisal guidance
    Discontinued

  2. Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1030)

    Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    15 January 2025

    Sections for TA1030

  3. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA557)

    This guidance has been updated and replaced by NICE technology appraisal guidance 683.

    Technology appraisal guidance
    Published
    10 January 2019

  4. Past appeals and decisions

    Past technology appraisal appeals and decisions